What is ARK Genomic Revolution ETF (ARKG)?
The ARK Genomic Revolution ETF is an exchange-traded fund that focuses on companies involved in the genomic and biotechnology sectors. It aims to provide exposure to firms engaged in the development and application of genomic technologies, including gene editing, genetic sequencing, and molecular diagnostics. The fund invests in a diversified portfolio of companies that contribute to advancements in healthcare, agriculture, and bioinformatics through genomic innovation. It is managed with an emphasis on identifying firms that are driving transformative changes in the understanding and manipulation of genetic material. The fund's holdings typically include a mix of established biotechnology companies and emerging firms at the forefront of genomic research and development. By concentrating on this specialized sector, the fund seeks to capture growth opportunities associated with the evolving landscape of genomics and its impact on various industries. The fund operates within the broader context of thematic investing, targeting long-term trends in science and technology.
ARK Genomic Revolution ETF Stock Price Today: Live Overview
The price today is shaped by current trading levels, with ARK Genomic Revolution ETF priced at $26.13. Its session range has been from $25.74 to $26.76, with a daily change percentage of -2.5141%.
FAQ: ARK Genomic Revolution ETF (ARKG)
What is the current price of ARKG stock?
The latest trading price is $26.13.
Does ARKG pay dividends?
ARK Genomic Revolution ETF does not pay dividends.
Does ARKG have a formal corporate presence or regional headquarters in the UAE?
ARK Genomic Revolution ETF does not have an official presence in the UAE and operates through financial intermediaries.
What is ARKG best known for?
The ETF is most famous for its focus on companies advancing genomic and biotechnological research.
What assets are typically shown together with ARKG?
Commonly shown alongside ARKG: Mistras Group Inc, UiPath Inc, Black Bear Minerals Limited
Latest shares articles



